Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study

Dong Hyun Oh1, Jung Ju Kim2, Jinnam Kim2, Hye Seong2, Se Ju Lee2, Yong Chan Kim2,3, Eun Jin Kim2,3, In Young Jung2,3, Woo Yong Jeong2,3, Su Jin Jeong2,3, Nam Su Ku2,3, Sang Hoon Han2,3, Jun Yong Choi2,3, Young Goo Song2,3 and June Myung Kim2,3

Abstract

Background: Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia.

Methods: Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared between a group receiving nafcillin and a group receiving glycopeptides.

Results: A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, \( p < 0.001 \)) and proportion of healthcare-associated infections (47.3 vs. 72.2%, \( p < 0.001 \)) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, \( p = 0.037 \)) and bone and joint infections (17.8 vs. 6.3%, \( p = 0.022 \)), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, \( p = 0.022 \)) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, \( p = 0.013 \)).

Conclusion: In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.

Keywords: Methicillin-susceptible Staphylococcus aureus, Nafcillin, Antistaphylococcal penicillin, Glycopeptides

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

*Staphylococcus aureus* (*S. aureus*) is one of the most common causes of community-acquired and healthcare-associated bacteremia [1]. The incidence of infection induced by methicillin-resistant *S. aureus* (MRSA) has been increasing [2, 3]. In Korea, a recent nationwide survey reported a methicillin-resistance rate of *S. aureus* of 66% in the general population [4]. Therefore, many clinicians therefore use glycopeptides such as vancomycin as their first choice of antibiotics for empirical treatment of *S. aureus* bacteremia to cover both MRSA and methicillin-susceptible *S. aureus* (MSSA) before confirming antibiotic susceptibility. However, some physicians continue to use the glycopeptide without changing to β-lactam antibiotics after confirmation of MSSA bacteremia.

Many studies comparing the efficacy of β-lactam antibiotics, including antistaphylococcal penicillin and glycopeptides, as empirical therapy for MSSA bacteremia have been conducted, and β-lactam agents have been found to be superior in the treatment of MSSA bacteremia compared with glycopeptides in these studies [5–8]. Wong et al. reported that empiric β-lactams was associated with earlier clearance of MSSA bacteremia compared to vancomycin (70.7 vs. 97.1 h, \( p = 0.007 \)) [5]. Additionally, Schweizer et al. reported that β-lactams showed protective effectiveness against mortality compared to vancomycin in patients with MSSA bacteremia (adjusted hazard ratio, 0.21; 95% CI, 0.09–0.47) [9]. However, there were few studies comparing glycopeptides and antistaphylococcal penicillin such as nafcillin alone as a treatment for MSSA bacteremia. This study aimed to compare the efficacy of nafcillin, an antistaphylococcal antibiotic, with that of glycopeptides including vancomycin and teicoplanin, as definitive therapy for patients with MSSA bacteremia.

Methods

Study population

We consecutively included patients with confirmed *S. aureus* bacteremia recruited from a single tertiary referral hospital from April 2012 to June 2016 in this retrospective cohort study. The referral hospital is a 2400-bed institution affiliated with Yonsei University College of Medicine in Seoul, South Korea. All participants were aged 18 years or older. Patients receiving a definitive therapy with nafcillin, vancomycin, or teicoplanin were included in this study. Patients who had MRSA infections or received treatment with other single antibiotics such as first generation cephalosporin, quinolone, or β-lactam/β-lactamase inhibitor combinations were excluded. Patients with bacteremia caused by other pathogens and those who died before the causative organism could be confirmed were also excluded. Participants were divided into the “nafcillin group” and the “glycopeptide group”. The study was approved by the institutional review board of the Yonsei University Health System Clinical Trial Center (#4-2017-0070).

Data collection

Baseline characteristics such as age, sex, and preexisting comorbidities including cardiovascular disease, cerebral vascular accidents, dementia, lung disease, autoimmune disease, peptic ulcer disease, chronic kidney disease, diabetes, liver disease, and malignancy were recorded. Data on the source of the bacteremia and on whether the patient's infection was community-acquired or healthcare-associated were collected. According to the source of bacteremia, we subdivided the patient sample into groups with catheter-related infection, pneumonia, urinary tract infection, skin and soft tissue infection, bone and joint infection, intra-abdominal infection, and primary bacteremia.

Laboratory tests were undertaken within the first 24 h after a culture was drawn. Tests included white blood cell (WBC) count, platelet counts, creatinine levels, estimated glomerular filtration rate, total bilirubin levels, prothrombin time (international normalized ratio), and C-reactive protein (CRP) levels. As the index of disease severity, the Pitt bacteremia score was calculated [10]. To assess the clinical outcome, we analyzed the patient data with respect to hospitalization duration, whether or not participants received intensive care unit (ICU) care, duration of stay at the ICU, persistent bacteremia, and all-cause 28-day mortality. The results of an antimicrobial susceptibility test, performed in accordance with the Clinical & Laboratory Standards Institute guidelines, were obtained from the patients’ medical records [11].

Definition

If bacteremia was identified within 48 h of admission and the participant had no history of admission to healthcare institutions within 3 months prior to admission, their infection was assumed to be community-acquired. If bacteremia was identified after 48 h or if the participant had an admission history within 3 months prior to admission, their infection was assumed to be healthcare-associated. Definitive therapy was defined as initiated or continued antibiotic treatment after identification of the pathogen in blood culture and in an antibiotic susceptibility test [12]. The source of infection, such as catheter-related infection, pneumonia, urinary tract infection, skin and soft tissue infection, bone and joint infection, and intra-abdominal infection was defined based on the criteria laid out by the Centers for Disease Control and Prevention, USA [13]. WBC counts equal to or above 10,000/mm³ are considered leukocytosis. Leukopenia is defined as WBC counts under 4000/mm³.
Thrombocytopenia is defined as platelet counts less than $150 \times 10^3/mm^3$. Persistent bacteremia is defined as the isolation of *S. aureus* in blood cultures obtained from peripheral veins for more than 7 consecutive days despite adequate antibiotic administration for more than 5 days. Mortality involving at least one of the following are defined as bacteremia-related mortality: (i) blood cultures were positive at the time of death; (ii) death occurred before the resolution of bacteremia; (iii) death occurred during hospitalization without other specific cause except bacteremia [14].

**Statistical analysis**
Continuous variables were expressed as mean ± standard deviation or median (interquartile range) and compared using the Student's *t*-test if the variables followed a normal distribution. Continuous variables with skewed distribution were compared using the Mann-Whitney *U*-test. The chi-squared test was used when all the categorical variables included in the analysis were 5 or more. If any of the categorical variables included in the analysis has a value of less than 5, it was analyzed using Fisher's exact test. To compare survival rates between the nafcillin group and the glycopeptide group, a Kaplan-Meier survival curve was used. The Cox regression model was used to analyze prognostic factors for mortality. All statistical analyses were performed using the Statistical Package for the Social Sciences 18.0 software (SPSS Inc., Chicago, IL, USA). *P* values under 0.05 were considered statistically significant.

**Results**
A total of 695 patients with *S. aureus* bacteremia were identified for screening. Three hundred and fifty patients with MRSA infection were excluded, and 35 patients who died before antimicrobial susceptibility was confirmed were also excluded. Additionally, 30 patients with coinfections with other bacteria and 92 patients treated with other antibiotics were excluded. Among the remaining 280 patients, 188 patients who underwent treatment with nafcillin, vancomycin, or teicoplanin were finally enrolled in this study. Ninety-one patients received nafcillin, and 97 patients received glycopeptides (vancomycin or teicoplanin) as definitive therapy (Fig. 1).

The mean age of the study participants was $62.37 \pm 15.14$ years, and 69% (*n* = 129) of all patients were male. With regard to underlying diseases, the patients in the glycopeptide group had a significantly higher rate of malignancy than the patients in the nafcillin group (28.6 vs. 60.8%, *p* < 0.001). There was no significant difference with regard to other comorbidities. Additionally, the patients in the glycopeptide group had a higher proportion of healthcare-associated infections (47.3 vs. 72.2%, *p* < 0.001). The most common infection source was skin and soft tissue infection (23.1%), followed by catheter-related infection and bone and joint infection (11.8%, respectively). Skin and soft tissue infections (30.0 vs. 16.7%, *p* = 0.037) and bone and joint infections were common in the nafcillin group. Laboratory tests showed that the median CRP level was significantly higher in the nafcillin group than in the glycopeptide group (139.60 vs. 107.61 mg/dL, *p* = 0.022). There was no significant difference in other laboratory tests (Table 1).

![Fig. 1 Study flow diagram](image)
With regard to the antimicrobial susceptibility of identified MSSA, we found a relatively high resistance rate to penicillin G (85.1%), erythromycin (17.1%), and clindamycin (15.4%). Resistance to other antibiotics was relatively low. There was no significant difference in resistance rates between the two patient groups except for clindamycin (8.8% vs. 21.6%, *p* = 0.016) (Additional file 1).

The median hospitalization period and the mean duration of stay at the ICU of all participants were 22.0 (14.0–39.5) days and 5.03 ± 14.10 days, respectively. The rate of persistent bacteremia was 9.6%. There was no difference between the two groups in terms of hospitalization period (22.0 vs. 22.0 days, *p* = 0.764). There were no significant differences in the duration of

### Table 1 Comparison of baseline characteristics and laboratory test results between the patient groups treated with either nafcillin or glycopeptides

| Characteristics                              | All patients (n = 188) | Nafcillin group (n = 91) | Glycopeptide group (n = 97) | *P* value |
|---------------------------------------------|------------------------|--------------------------|-----------------------------|-----------|
| Age, years, mean ± SD                       | 62.37 ± 15.14          | 64.38 ± 14.53            | 60.46 ± 15.54               | 0.076 *a* |
| Male, (%)                                    | 129 (69.0)             | 61 (67.0)                | 68 (70.8)                   | 0.636 *b* |
| Underlying comorbidities, yes (%)           |                        |                          |                             |           |
| Cardiovascular disease                       | 55 (29.3)              | 29 (31.9)                | 26 (26.8)                   | 0.522 *b* |
| Cerebral vascular accident                  | 19 (10.1)              | 12 (13.2)                | 7 (7.2)                     | 0.227 *b* |
| Dementia                                     | 5 (2.7)                | 1 (1.1)                  | 4 (4.1)                     | 0.370 *c* |
| Lung disease                                 | 14 (7.4)               | 8 (8.8)                  | 6 (6.2)                     | 0.584 *b* |
| Autoimmune disease                          | 10 (5.3)               | 4 (4.4)                  | 6 (6.2)                     | 0.749 *c* |
| Peptic ulcer disease                        | 10 (5.3)               | 6 (6.6)                  | 4 (4.1)                     | 0.527 *c* |
| Chronic kidney disease                      | 39 (20.7)              | 23 (25.3)                | 16 (16.5)                   | 0.153 *b* |
| Diabetes                                     | 62 (33.0)              | 35 (38.5)                | 27 (27.8)                   | 0.162 *b* |
| Liver disease                                | 23 (12.2)              | 8 (8.8)                  | 15 (15.5)                   | 0.187 *b* |
| Malignancy                                   | 85 (45.2)              | 26 (28.6)                | 59 (60.8)                   | <0.001 *b*|
| CA vs. HCA, HCA (%)                          | 113 (60.1)             | 43 (47.3)                | 70 (72.2)                   | <0.001 *b*|
| Pit bacteremia score, mean ± SD             | 1.56 ± 2.55            | 1.42 ± 2.39              | 1.69 ± 2.71                 | 0.465 *a* |
| Infection focus, yes (%)                    |                        |                          |                             |           |
| Catheter-related infection                  | 22 (11.8)              | 12 (13.3)                | 10 (10.4)                   | 0.651 *b* |
| Pneumonia                                    | 8 (4.3)                | 1 (1.1)                  | 7 (7.3)                     | 0.066 *c* |
| Urinary tract infection                     | 7 (3.8)                | 9 (6.7)                  | 1 (1.0)                     | 0.058 *c* |
| Skin and Soft tissue infection              | 43 (23.1)              | 27 (30.0)                | 16 (16.7)                   | 0.037 *b* |
| Bone and Joint infection                    | 22 (11.8)              | 16 (17.8)                | 6 (6.3)                     | 0.022 *b* |
| Intra-abdominal infection                   | 13 (7.0)               | 3 (3.3)                  | 10 (10.4)                   | 0.083 *c* |
| Primary bacteremia                          | 74 (39.8)              | 27 (30.0)                | 47 (49.0)                   | 0.011 *b* |
| Laboratory tests                            |                        |                          |                             |           |
| WBC, /mm³, median (IQR)                     | 10,150 (7,635–14,770)  | 10,450 (8,120–15,280)    | 9,860 (5,485–14,615)        | 0.064 *d* |
| Leukocytosis or Leukopenia, yes (%)         | 116 (61.7)             | 50 (54.9)                | 66 (68.0)                   | 0.073 *b* |
| Platelet counts, x10³/mm³, median (IQR)     | 169 (95–250)           | 182 (115–257)            | 164 (83–250)                | 0.190 *d* |
| Thrombocytopenia, yes (%)                   | 82 (43.6)              | 36 (39.6)                | 46 (47.4)                   | 0.305 *b* |
| eGFR, mL/min/mm³, mean ± SD                | 62.88 ± 28.60          | 62.38 ± 28.27            | 63.35 ± 29.06               | 0.818 *a* |
| Total bilirubin, mg/dL, median (IQR)        | 0.8 (0.5–1.4)          | 0.8 (0.5–1.3)            | 0.8 (0.5–1.4)               | 0.452 *d* |
| Prothrombin time (INR), median (IQR)        | 1.12 (1.01–1.29)       | 1.13 (1.02–1.28)         | 1.11 (1.01–1.32)            | 0.895 *d* |
| CRP, mg/dL, median (IQR)                    | 121.01 (56.34–200.85)  | 139.60 (79.68–219.00)    | 107.61 (42.19–192.90)       | 0.022 *d* |

Abbreviations: SD standard deviation, CA community-acquired, HCA healthcare-associated, WBC white blood cell, IQR interquartile range, eGFR estimated glomerular filtration rate, INR international normalized ratio, CRP C-reactive protein

*Student’s t-test
Pearson’s χ²-test
Fisher’s exact test
Mann-Whitney U-test, median (interquartile range)
ICU stay (3.71 vs. 6.26 days, \(p = 0.217\)) and in the ratio of persistent bacteremia (12.2 vs. 7.2%, \(p = 0.323\)) between the two patient groups. (Table 2, Fig. 2). There was a significant difference between the two patient groups in all-cause 28-day mortality (7.7 vs. 20.6%, \(p = 0.013\)) and bacteremia-related 28-day mortality (4.4 vs. 14.4%, \(p = 0.025\)). Additionally, the Cox regression analysis showed that the use of glycopeptides was the significant prognostic factor for mortality when adjusting for malignancy, healthcare-associated infection, and CRP (Hazard ratio, 2.615; 95% CI, 1.105–6.186, \(p = 0.029\)) (Additional file 2).

Discussion

\textit{S. aureus} bacteremia is a very severe clinical condition that clinicians often experience. Since the infection rate caused by MRSA is increasing, many clinicians use the glycopeptide empirically. However, despite of confirming MSSA bacteremia via bacterial culture, it is not uncommon to maintain glycopeptide as definitive therapy for the reason that severe comorbidities and disease severity. There have been many studies related to the choice of a definitive therapeutic agent for MSSA bacteremia, but no study had compared prognosis with glycopeptide with nafcillin alone, an antistaphylococcal agent. In our current study, we found that the 28-day mortality rate was significantly lower in a group of patients with MSSA bacteremia receiving definitive therapy with nafcillin compared to a group receiving treatment with this finding suggests that nafcillin should be considered as the first choice for definitive antimicrobial therapy in MSSA bacteremia.

Our finding of higher mortality in the vancomycin group is in accordance with findings from several recent studies. Mcdanel et al. reported a higher mortality rate in patients who received vancomycin monotherapy compared with patients who received \(\beta\)-lactam monotherapy, as definitive therapy for MSSA bacteremia, after adjustment for confounding factors such as severity of illness, comorbidities, age, and others [7]. Kim et al. reported higher mortality in patients who were treated with vancomycin for MSSA bacteremia compared with patients receiving \(\beta\)-lactam agents [6].

Some explanations for the relative inferiority of vancomycin in the treatment of MSSA have been proposed [15]. Generally, \(\beta\)-lactam agents are classified as bactericidal to MSSA, whereas the bactericidal effect of vancomycin is lower than that of \(\beta\)-lactam agents [15, 16]. Furthermore, vancomycin has a relatively narrow therapeutic range as compared to \(\beta\)-lactam agents, pharmacologically [15]. Additionally, because teicoplanin is a bacteriostatic agent with similar efficacy as vancomycin, teicoplanin also poses problems that is similar with vancomycin in the treatment of MSSA [17].

In this study, the prevalence of malignancy and the proportion of healthcare-associated infections were higher in the glycopeptide group than in the nafcillin group. In addition, skin and soft tissue infection as well as bone and joint infection were more common in the nafcillin group than in the glycopeptide group. However, the use of glycopeptides was found to be the significant prognostic factor for mortality when adjusting for these variables. Thus, despite several confounding variables, the choice of antibiotics, in this case nafcillin versus glycopeptides, in the treatment of MSSA bacteremia is an important factor affecting patient mortality.

On the other hand, we found no significant difference in persistent bacteremia in this study. Kim et al. reported that there was no statistical difference in eradication of infection foci between a \(\beta\)-lactam treatment group and a vancomycin treatment group in patients with MSSA bacteremia [6]. However, Wong \textit{et al.} reported a significant difference in the frequency of prolonged bacteremia between a \(\beta\)-lactam treatment group and a vancomycin treatment group [5]. Furthermore, Park et al. reported significant differences in bacteremia duration between a \(\beta\)-lactam treatment group, a vancomycin treatment group, and a combination treatment group [18].

This study has several limitations. First, this is a retrospective cohort study and it is thus subject to selection bias. Second, all data were collected from a single center, so that generalization of these results to other institutions

### Table 2 Clinical outcome of the different treatments

| Characteristics | All patients \((n = 188)\) | Nafcillin group \((n = 91)\) | Glycopeptide group \((n = 97)\) | \(P\) value |
|-----------------|--------------------------|--------------------------|--------------------------|------------|
| Hospitalization period, days, median (IQR) | 22.0 (14.0–39.5) | 22.0 (12.0–41.0) | 22.0 (15.0–36.0) | 0.764<sup>c</sup> |
| ICU stay, days, mean ± SD | 5.03 ± 14.10 | 3.71 ± 12.47 | 6.26 ± 15.44 | 0.217<sup>a</sup> |
| Persistent bacteremia, (%) | 18 (9.6) | 11 (12.2) | 7 (7.2) | 0.323<sup>b</sup> |
| All-cause 28-day mortality, yes (%) | 27 (14.4) | 7 (7.7) | 20 (20.6) | 0.013<sup>b</sup> |

*Abbreviations: IQR interquartile range, ICU intensive care unit, SD standard deviation
<sup>a</sup>Student’s \(t\)-test
<sup>b</sup>Pearson’s \(\chi^2\) test
<sup>c</sup>Mann-Whitney \(U\)-test, median (interquartile range)
might be questionable. Additional prospective studies with more selective and larger populations involving multiple centers are necessary.

**Conclusion**
In conclusion, we find that all-cause 28-day mortality in MSSA bacteremia is higher in patients receiving glycopeptides as definitive therapy compared to patients receiving nafcillin. Therefore, the use of nafcillin should be a first choice for definitive antimicrobial treatment in MSSA bacteremia.

### Additional files

- **Additional file 1**: Supplement 1. Antibiotic resistance rate of identified Staphylococcus aureus. (DOCX 21 kb)
- **Additional file 2**: Multivariate analysis of prognostic factors for predicting mortality in patients with MSSA bacteremia, with adjustments for prevalence of malignancy, healthcare-associated infections, and CRP. (DOCX 13 kb)

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article and its Additional files.

**Authors’ contributions**
Conception and design of study: DHO and NSK. Acquisition of data: JJK, JK, HS, SJL, YCK, EJK, IYJ and WYJ. Data analysis and interpretation: DHO and NSK. Drafting of manuscript and critical revision: SJJ, SHH, JYC, YGS, JMK and NSK. Approval of final version of manuscript: DHO, JJK, JK, HS, SJL, YCK, EJK, IYJ, WYJ, SJJ, NSK, SHH, JYC, YGS, and JMK.

**Ethics approval and consent to participate**
The study was approved by the institutional review board of the Yonsei University Health System Clinical Trial Center (#4–2017-0070). The informed consent was waived because this study was a retrospective study with review of related data through the electronic medical record.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1Department of Internal Medicine, Seoul Medical Center, 156 Sinnae-ro, Jungnang-gu, 02053 Seoul, South Korea. 2Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea. 3AIDS Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul, South Korea.
References
1. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus Aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362–86.
2. National Nosocomial Infections Surveillance S. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8):470–85.
3. Klevens RM, Morrison MA, Nadle J, Petit S, Genshman K, Ray S, Harrison LH, Lynfield R, Dunyati G, Townes JM, et al. Invasive methicillin-resistant Staphylococcus Aureus infections in the united states. JAMA. 2007;298(15):1763–71.
4. Yong D, Shin HB, Cho J, Lee WG, Ha GY, Choi TY, Jeong SH, Lee K, Chong Y, et al. Increase in the prevalence of Carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-Typhoidal salmonella species in Korea: a KONSAR study conducted in 2011. Infect Chemother. 2014;46(3):94–93.
5. Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of beta-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus Aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016;15:27.
6. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Cho KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus Aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.
7. McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Christel J, PA, Dawson JD, Jiang L, Goto M, Schweizer ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus Aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361–7.
8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine BP, Murray BE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.
9. McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Christel J, PA, Dawson JD, Jiang L, Goto M, Schweizer ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus Aureus bacteremia. BMJ Infect Dis. 2011;11:279.
10. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, Murdoch D, Pottumarthy S, Roberts SA, Swager C, et al. Prospective study of 424 cases of Staphylococcus Aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001;31(2):97–103.
11. Performance standards for antimicrobial disk susceptibility tests. In: standard-tenth edn. Wayne, Pennsylvania: Clinical and Laboratory Standards Institution; 2009: M02-A9.
12. Rasmussen JB, Knudsen JD, Arpi M, Schonheyder HC, Benfield T, Ostergaard C. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus Aureus bacteremia: a propensity-score adjusted retrospective cohort study. J Antimicrob Chemother. 2014;69(2):506–14.
13. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.
14. Sterling SA, Puskarich MA, Glass AF, Guirgis F, Jones AE. The impact of the Sepsis-3 septic shock definition on previously defined septic shock patients. Crit Care Med. 2017;
15. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42(Suppl 1):S51–7.
16. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl 1):S13–24.
17. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996;37(2):209–22.
18. Park GE, Ko JH, Cho SY, Ha YE, Lee NY, Kang CJ, Chung DR, Song JH, Peck KR. Empirical combination of a beta-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus Aureus bacteremia, compared to vancomycin monotherapy. Eur J Clin Microbiol Infect Dis. 2017;